Review



phosphorylated p egfr tyr992  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc phosphorylated p egfr tyr992
    <t>EGFR,</t> <t>p-EGFR</t> <t>(Tyr992),</t> SYK, EGF, and AREG protein expression in APL patient samples. (A) Western blotting analysis of EGFR, p-EGFR (Tyr992), SYK, and β-actin protein levels in CD34 + cells isolated from normal BM of one healthy adult volunteer and 10 representative primary APL samples collected at diagnosis. HeLa cells served as a positive control to assess EGFR and p-EGFR (Tyr992) expression, and MV4-11 cell extracts were used as a positive control for SYK expression. EGFR and p-EGFR (Tyr992) were detectable when exposed for 180 seconds (sec). (B) EGF levels in BM plasma samples from healthy donors (n=15) and APL patients at diagnosis (n=16). (C) Plasma AREG levels in BM from healthy donors (n=20) and APL patients at diagnosis (n=17). (**) p < 0.01 (Mann-Whitney U-test).
    Phosphorylated P Egfr Tyr992, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 188 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated p egfr tyr992/product/Cell Signaling Technology Inc
    Average 95 stars, based on 188 article reviews
    phosphorylated p egfr tyr992 - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells"

    Article Title: The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2021.686445

    EGFR, p-EGFR (Tyr992), SYK, EGF, and AREG protein expression in APL patient samples. (A) Western blotting analysis of EGFR, p-EGFR (Tyr992), SYK, and β-actin protein levels in CD34 + cells isolated from normal BM of one healthy adult volunteer and 10 representative primary APL samples collected at diagnosis. HeLa cells served as a positive control to assess EGFR and p-EGFR (Tyr992) expression, and MV4-11 cell extracts were used as a positive control for SYK expression. EGFR and p-EGFR (Tyr992) were detectable when exposed for 180 seconds (sec). (B) EGF levels in BM plasma samples from healthy donors (n=15) and APL patients at diagnosis (n=16). (C) Plasma AREG levels in BM from healthy donors (n=20) and APL patients at diagnosis (n=17). (**) p < 0.01 (Mann-Whitney U-test).
    Figure Legend Snippet: EGFR, p-EGFR (Tyr992), SYK, EGF, and AREG protein expression in APL patient samples. (A) Western blotting analysis of EGFR, p-EGFR (Tyr992), SYK, and β-actin protein levels in CD34 + cells isolated from normal BM of one healthy adult volunteer and 10 representative primary APL samples collected at diagnosis. HeLa cells served as a positive control to assess EGFR and p-EGFR (Tyr992) expression, and MV4-11 cell extracts were used as a positive control for SYK expression. EGFR and p-EGFR (Tyr992) were detectable when exposed for 180 seconds (sec). (B) EGF levels in BM plasma samples from healthy donors (n=15) and APL patients at diagnosis (n=16). (C) Plasma AREG levels in BM from healthy donors (n=20) and APL patients at diagnosis (n=17). (**) p < 0.01 (Mann-Whitney U-test).

    Techniques Used: Expressing, Western Blot, Isolation, Biomarker Discovery, Positive Control, Clinical Proteomics, MANN-WHITNEY



    Similar Products

    phosphorylated p egfr tyr992  (Cell Signaling Technology Inc)
    95
    Cell Signaling Technology Inc phosphorylated p egfr tyr992
    <t>EGFR,</t> <t>p-EGFR</t> <t>(Tyr992),</t> SYK, EGF, and AREG protein expression in APL patient samples. (A) Western blotting analysis of EGFR, p-EGFR (Tyr992), SYK, and β-actin protein levels in CD34 + cells isolated from normal BM of one healthy adult volunteer and 10 representative primary APL samples collected at diagnosis. HeLa cells served as a positive control to assess EGFR and p-EGFR (Tyr992) expression, and MV4-11 cell extracts were used as a positive control for SYK expression. EGFR and p-EGFR (Tyr992) were detectable when exposed for 180 seconds (sec). (B) EGF levels in BM plasma samples from healthy donors (n=15) and APL patients at diagnosis (n=16). (C) Plasma AREG levels in BM from healthy donors (n=20) and APL patients at diagnosis (n=17). (**) p < 0.01 (Mann-Whitney U-test).
    Phosphorylated P Egfr Tyr992, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated p egfr tyr992/product/Cell Signaling Technology Inc
    Average 95 stars, based on 1 article reviews
    phosphorylated p egfr tyr992 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    EGFR, p-EGFR (Tyr992), SYK, EGF, and AREG protein expression in APL patient samples. (A) Western blotting analysis of EGFR, p-EGFR (Tyr992), SYK, and β-actin protein levels in CD34 + cells isolated from normal BM of one healthy adult volunteer and 10 representative primary APL samples collected at diagnosis. HeLa cells served as a positive control to assess EGFR and p-EGFR (Tyr992) expression, and MV4-11 cell extracts were used as a positive control for SYK expression. EGFR and p-EGFR (Tyr992) were detectable when exposed for 180 seconds (sec). (B) EGF levels in BM plasma samples from healthy donors (n=15) and APL patients at diagnosis (n=16). (C) Plasma AREG levels in BM from healthy donors (n=20) and APL patients at diagnosis (n=17). (**) p < 0.01 (Mann-Whitney U-test).

    Journal: Frontiers in Oncology

    Article Title: The Combination of Gefitinib With ATRA and ATO Induces Myeloid Differentiation in Acute Promyelocytic Leukemia Resistant Cells

    doi: 10.3389/fonc.2021.686445

    Figure Lengend Snippet: EGFR, p-EGFR (Tyr992), SYK, EGF, and AREG protein expression in APL patient samples. (A) Western blotting analysis of EGFR, p-EGFR (Tyr992), SYK, and β-actin protein levels in CD34 + cells isolated from normal BM of one healthy adult volunteer and 10 representative primary APL samples collected at diagnosis. HeLa cells served as a positive control to assess EGFR and p-EGFR (Tyr992) expression, and MV4-11 cell extracts were used as a positive control for SYK expression. EGFR and p-EGFR (Tyr992) were detectable when exposed for 180 seconds (sec). (B) EGF levels in BM plasma samples from healthy donors (n=15) and APL patients at diagnosis (n=16). (C) Plasma AREG levels in BM from healthy donors (n=20) and APL patients at diagnosis (n=17). (**) p < 0.01 (Mann-Whitney U-test).

    Article Snippet: The proteins were transferred to a polyvinylidene difluoride membrane (Amersham Hybond-P; GE Healthcare, Memphis, TN, USA) that was probed with antibodies against total EGFR (#2232, polyclonal, 1:1000) and phosphorylated (p-)EGFR (Tyr992) (#2235, polyclonal, 1:1000) (both from Cell Signaling Technology, Danvers, MA, USA); SYK (#1240, clone: 4D10, 1:1000; Santa Cruz Biotechnology, Santa Cruz, CA, USA); and β-actin (#A5441, clone: AC-15, 1:60 000; Sigma-Aldrich).

    Techniques: Expressing, Western Blot, Isolation, Biomarker Discovery, Positive Control, Clinical Proteomics, MANN-WHITNEY